CD4 and neoplasm: For example, sorafenib treatment increases intratumoral infiltrating of F4/80+ tumor-associated macrophages, CD4+CD25+FoxP3+ regulatory T cells, CCL2+/CCL17+ tumor-associated neutrophils and CD11b+Gr-1+ myeloid cells in human and murine HCC models [37, 41].